PDF(Pubmed)
Abstract：
UNASSIGNED: HIV-1 and Mtb are characterized by immune activation and unbalances production of cytokines, but the expression of IL33 in HIV/TB coinfection remain understudied. This study aimed to evaluate the level of IL-33 in plasma of HIV and M. tuberculosis (HIV/TB) coinfected patients compared to patients with respective mono infections in Yaoundé.
UNASSIGNED: a cross-sectional study was conducted among patients attending the pneumology service and HIV treatment center of the Yaoundé Jamot Hospital. Plasma samples of 157 HIV/TB coinfected patients (n =26, 50% males and 50% females, mean age 39), HIV-1 monoinfected patients (n = 41, 41% males and 59% females, mean age 35), TB monoinfected patients (n = 48, 56% males and 44% females, mean age 37) and healthy controls (n = 42, 29% males and 71% females, mean age 32) were examined by enzyme-linked immunoassay (ELISA) to detect the levels of IL-33 cytokine.
UNASSIGNED: plasma level of IL-33 were higher in HIV/TB coinfected (33.1±30.9 pg/ml) and TB monoinfected individuals (15.1±2.9 pg/ml) compared to healthy controls (14.0±3.4 pg/ml) and could not be detected in most of the HIV-1 monoinfected individuals (12.6±8.7 pg/ml). Interestingly, the increased plasma level of IL-33 in HIV/TB coinfected patients showed a statistically significant difference between healthy controls (33.1±30.9 pg/ml vs 14.0±3.4 pg/ml, P<0.0001) and HIV-1 monoinfected patients (33.1±30.9 pg/ml vs 12.6±8.7 pg/ml, P=0.0002). We further found that IL-33 was higher in patients with high viral load group (40.6±59.7 pg/ml vs 12.6±1.8 pg/ml), P= 0.47) whereas patients under highly active antiretroviral therapy (HAART) showed decreased level of IL-33 concentration as the number of years under ART increased. Our data showed a positive association between plasma IL-33 and viral load in the context of HIV/TB coinfection in our study population with a positive Pearson coefficient of r=0.21.
UNASSIGNED: this study indicates that plasma level of IL-33 differs among HIV/TB coinfected patients and respective monoinfections patients. The increased level of plasma IL-33 reveals that IL-33 measurement in HIV-1 monoinfected patients may represent an early predictor of development of tuberculosis.
UNASSIGNED: a cross-sectional study was conducted among patients attending the pneumology service and HIV treatment center of the Yaoundé Jamot Hospital. Plasma samples of 157 HIV/TB coinfected patients (n =26, 50% males and 50% females, mean age 39), HIV-1 monoinfected patients (n = 41, 41% males and 59% females, mean age 35), TB monoinfected patients (n = 48, 56% males and 44% females, mean age 37) and healthy controls (n = 42, 29% males and 71% females, mean age 32) were examined by enzyme-linked immunoassay (ELISA) to detect the levels of IL-33 cytokine.
UNASSIGNED: plasma level of IL-33 were higher in HIV/TB coinfected (33.1±30.9 pg/ml) and TB monoinfected individuals (15.1±2.9 pg/ml) compared to healthy controls (14.0±3.4 pg/ml) and could not be detected in most of the HIV-1 monoinfected individuals (12.6±8.7 pg/ml). Interestingly, the increased plasma level of IL-33 in HIV/TB coinfected patients showed a statistically significant difference between healthy controls (33.1±30.9 pg/ml vs 14.0±3.4 pg/ml, P<0.0001) and HIV-1 monoinfected patients (33.1±30.9 pg/ml vs 12.6±8.7 pg/ml, P=0.0002). We further found that IL-33 was higher in patients with high viral load group (40.6±59.7 pg/ml vs 12.6±1.8 pg/ml), P= 0.47) whereas patients under highly active antiretroviral therapy (HAART) showed decreased level of IL-33 concentration as the number of years under ART increased. Our data showed a positive association between plasma IL-33 and viral load in the context of HIV/TB coinfection in our study population with a positive Pearson coefficient of r=0.21.
UNASSIGNED: this study indicates that plasma level of IL-33 differs among HIV/TB coinfected patients and respective monoinfections patients. The increased level of plasma IL-33 reveals that IL-33 measurement in HIV-1 monoinfected patients may represent an early predictor of development of tuberculosis.
摘要：
■HIV-1和Mtb的特征是免疫激活和细胞因子的不平衡产生，但IL33在HIV/TB合并感染中的表达仍未得到充分研究。这项研究旨在评估与雅温得各自单一感染的患者相比，HIV和结核分枝杆菌（HIV/TB）共感染患者血浆中IL-33的水平。
在雅温得Jamot医院的肺炎服务和HIV治疗中心就诊的患者中进行了一项横断面研究。157名HIV/TB合并感染患者的血浆样本（n=26，男性50％，女性50％，平均年龄39），HIV-1单感染患者（n=41，男性41％，女性59％，平均年龄35），结核病单感染患者(n=48，56%男性和44%女性，平均年龄37岁)和健康对照(n=42，29%男性和71%女性，平均年龄32）通过酶联免疫测定（ELISA）检测IL-33细胞因子的水平。
■HIV/TB合并感染（33.1±30.9pg/ml）和TB单感染个体（15.1±2.9pg/ml）的IL-33血浆水平高于健康对照组（14.0±3.4pg/ml），并且在大多数HIV-1单感染个体（12.6±8.7pg/ml）中无法检测到。有趣的是,HIV/TB合并感染患者的血浆IL-33水平升高在健康对照组之间具有统计学意义（33.1±30.9pg/mlvs14.0±3.4pg/ml，P<0.0001）和HIV-1单感染患者（33.1±30.9pg/mlvs12.6±8.7pg/ml，P=0.0002)。我们进一步发现，IL-33在高病毒载量组患者中更高（40.6±59.7pg/mlvs12.6±1.8pg/ml），P=0.47），而接受高效抗逆转录病毒治疗（HAART）的患者随着接受ART治疗年数的增加，IL-33浓度水平降低。我们的数据显示，在我们的研究人群中，在HIV/TB合并感染的情况下，血浆IL-33与病毒载量之间呈正相关，Pearson系数为r=0.21。
■这项研究表明，IL-33的血浆水平在HIV/TB共感染患者和各自的单一感染患者之间不同。血浆IL-33水平的升高表明，在HIV-1单感染患者中的IL-33测量可能代表结核病发展的早期预测因子。
在雅温得Jamot医院的肺炎服务和HIV治疗中心就诊的患者中进行了一项横断面研究。157名HIV/TB合并感染患者的血浆样本（n=26，男性50％，女性50％，平均年龄39），HIV-1单感染患者（n=41，男性41％，女性59％，平均年龄35），结核病单感染患者(n=48，56%男性和44%女性，平均年龄37岁)和健康对照(n=42，29%男性和71%女性，平均年龄32）通过酶联免疫测定（ELISA）检测IL-33细胞因子的水平。
■HIV/TB合并感染（33.1±30.9pg/ml）和TB单感染个体（15.1±2.9pg/ml）的IL-33血浆水平高于健康对照组（14.0±3.4pg/ml），并且在大多数HIV-1单感染个体（12.6±8.7pg/ml）中无法检测到。有趣的是,HIV/TB合并感染患者的血浆IL-33水平升高在健康对照组之间具有统计学意义（33.1±30.9pg/mlvs14.0±3.4pg/ml，P<0.0001）和HIV-1单感染患者（33.1±30.9pg/mlvs12.6±8.7pg/ml，P=0.0002)。我们进一步发现，IL-33在高病毒载量组患者中更高（40.6±59.7pg/mlvs12.6±1.8pg/ml），P=0.47），而接受高效抗逆转录病毒治疗（HAART）的患者随着接受ART治疗年数的增加，IL-33浓度水平降低。我们的数据显示，在我们的研究人群中，在HIV/TB合并感染的情况下，血浆IL-33与病毒载量之间呈正相关，Pearson系数为r=0.21。
■这项研究表明，IL-33的血浆水平在HIV/TB共感染患者和各自的单一感染患者之间不同。血浆IL-33水平的升高表明，在HIV-1单感染患者中的IL-33测量可能代表结核病发展的早期预测因子。
